Which skin conditions are treated with tacrolimus (tacrolimus ointment)?

Skin Conditions Treated with Tacrolimus Ointment

Tacrolimus ointment is FDA-approved for atopic dermatitis in patients 2 years and older, and is used off-label for facial and intertriginous psoriasis, vitiligo, atopic conjunctivitis/vernal keratoconjunctivitis (eyelid involvement), and various other inflammatory dermatoses.

FDA-Approved Indication

Atopic Dermatitis

• Primary indication: Tacrolimus 0.03% and 0.1% ointment are FDA-approved for short-term and intermittent long-term treatment of moderate-to-severe atopic dermatitis in patients ≥2 years old who are unresponsive to or intolerant of conventional therapies 1, 2
• Dosing: 0.03% for children 2-15 years; 0.1% for patients ≥16 years, applied twice daily 2
• Efficacy: High-quality evidence demonstrates tacrolimus 0.1% is superior to low-potency corticosteroids and pimecrolimus 1%, with comparable efficacy to moderate-to-potent corticosteroids but without risk of skin atrophy 3
• Key advantage: Does not cause skin atrophy unlike topical corticosteroids, making it particularly valuable for long-term management 2, 3

Off-Label Dermatologic Uses

Psoriasis (Facial and Intertriginous)

Tacrolimus 0.1% ointment is specifically recommended for facial and genital psoriasis where corticosteroid-related atrophy is a concern 4, 5

• Facial psoriasis: 65% of patients achieved clear or almost clear skin after 8 weeks with tacrolimus 0.1% versus 31% with placebo 5
• Intertriginous psoriasis: Effective for body folds, genital areas where thin skin makes corticosteroid use problematic 5
• Pediatric psoriasis: Recommended for face and genital regions in children (strength of recommendation C, level of evidence II-III) 4
• Important limitation: NOT effective for thick plaque psoriasis on trunk and extremities—penetration through thick plaques is inadequate 5

Vitiligo

• Tacrolimus demonstrates efficacy for repigmentation, particularly in Fitzpatrick skin types 3-4 6, 7
• Head and neck lesions respond better than body/extremity lesions across all skin types 7
• Often combined with phototherapy (excimer laser) for enhanced repigmentation 6
• In children, tacrolimus should be considered as an alternative to high-potency corticosteroids due to better safety profile 6

Atopic and Vernal Conjunctivitis (Eyelid Involvement)

• Eyelid application: Tacrolimus 0.03% or 0.1% ointment for eyelid involvement in patients ≥2 years 8
• Used when topical corticosteroids, cyclosporine, or antiallergy medications have failed 8
• Dosing by age: 0.03% for ages 2-15 years; either 0.03% or 0.1% for ≥16 years 8

Other Reported Uses (Limited Evidence)

Based on case series and small studies, tacrolimus has shown benefit in 9, 10, 11:

• Lichen planus (including erosive mucosal forms)
• Pyoderma gangrenosum
• Lichen sclerosus
• Contact dermatitis
• Steroid-induced rosacea
• Alopecia areata
• Graft-versus-host disease

However, these indications lack robust clinical trial data and remain investigational.

Critical Safety Considerations

Black Box Warning

• FDA issued black box warning in 2005 regarding potential malignancy risk due to lack of long-term safety data 5
• Current evidence: No causal link established between topical calcineurin inhibitors and cancer in humans after >15 years of use 5, 3
• Systemic absorption is minimal and decreases as skin heals 3

Specific Precautions

• Avoid in immunocompromised patients 1
• Pregnancy Category C: Found in human milk, not recommended for nursing mothers 5
• Contraindicated in severe skin barrier defects (Netherton syndrome, lamellar ichthyosis) due to increased systemic absorption 1, 3
• Use caution with concurrent UV therapy in psoriasis patients—animal studies suggest potential increased tumor risk, though not observed in humans 5

Common Adverse Effects

• Burning and stinging at application site (most common, usually transient) 5
• More pronounced with tacrolimus than pimecrolimus 5
• Can be mitigated by not applying immediately after bathing 5
• No skin atrophy unlike corticosteroids 5, 3

Practical Application Algorithm

For atopic dermatitis:

1. Use as FDA-approved for moderate-to-severe disease
2. Apply twice daily to affected areas
3. Consider for maintenance therapy (intermittent long-term use)

For facial/genital psoriasis:

1. First-line for these sensitive areas to avoid corticosteroid atrophy 4, 5
2. Use 0.1% concentration twice daily
3. Expect response within 2-8 weeks

For vitiligo:

1. Consider especially in Fitzpatrick types 3-4
2. Prioritize head/neck lesions for best response
3. May combine with phototherapy for enhanced effect

When NOT to use:

• Thick plaque psoriasis on body
• Immunocompromised patients
• Severe barrier defects
• Pregnancy/breastfeeding (relative contraindication)